-+ 0.00%
-+ 0.00%
-+ 0.00%

BioLineRx's GLIX1 Shows Synergy With PARP Inhibitors in Preclinical Ovarian Cancer Studies

PUBT·10/23/2026 11:03:04
BioLineRx's GLIX1 Shows Synergy With PARP Inhibitors in Preclinical Ovarian Cancer Studies
  • BioLineRx and Hemispherian presented preclinical results at ESMO 2026 showing GLIX1 synergy with PARP inhibitors in homologous recombination-proficient ovarian cancer.
  • Combinations with three PARP inhibitors produced reproducible synergy across multiple cell lines, with ZIP synergy scores of 10.9-43.2.
  • In a 28-day patient-derived xenograft study, low-dose GLIX1 with olaparib significantly inhibited tumor growth versus vehicle control.
  • The combination outperformed either drug alone at its optimal dose, with tumor growth inhibition comparable to cisplatin.
  • GLIX1 is in a Phase 1/2a glioblastoma trial, with an ovarian cancer arm planned for the expansion phase.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230700PR_NEWS_USPR_____LN79078) on October 23, 2026, and is solely responsible for the information contained therein.